The biotech VC with a nine-fold return
A Flagship Pioneering fund delivered a nine-fold return to investors, making it the best-performing biotech venture fund in a sweeping look at the industry’s performance.
As STAT’s Kate Sheridan reports, Flagship’s 2012 fund beat out more than 15 others in an analysis based on data collected through public records requests and reports from outside investors. That fund invested in at least 11 companies, including Moderna, Editas Medicine, and Axcella Health.
Those results come from a new STAT report that ranks a host of biotech VC funds, using previously unpublished results from the limited partners that supply the likes of Flagship with investment capital.
Read more and download the report.
As STAT’s Kate Sheridan reports, Flagship’s 2012 fund beat out more than 15 others in an analysis based on data collected through public records requests and reports from outside investors. That fund invested in at least 11 companies, including Moderna, Editas Medicine, and Axcella Health.
Those results come from a new STAT report that ranks a host of biotech VC funds, using previously unpublished results from the limited partners that supply the likes of Flagship with investment capital.
Read more and download the report.
No hay comentarios:
Publicar un comentario